On the recordJuly 28, 2021
H.R. 3, the drug pricing bill, is not the path forward.
Source
congress.govEditor's note · Context
Guthrie argues against H.R. 3, claiming it jeopardizes innovation for neurodegenerative disease treatments.
Share & report
More from James Guthrie
Jul 28, 2021
Thank you, Madam Chair, for the recognition, and the first question is for Dr. Koroshetz and Dr. Hodes.
Oct 25, 2021
As co-chair of the Congressional Apprenticeship Caucus, I have been a strong supporter of apprenticeships, and believe they are a great avenue for workers and employees.
Dec 7, 2021
However, we cannot talk about advancing healthcare innovation without addressing the harmful drug pricing provision the Democrats' reckless tax and spending spree bill that will ultimately restrict patients' access to timely care and lead to less cures.
Other voices in this conversation
